Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival by Rubert, Joëlle et al.
RESEARCH ARTICLE Open Access









V617F mutation plays a major role in the pathogenesis of myeloproliferative neoplasms and
is found in the vast majority of patients suffering from polycythemia vera and in roughly every second patient
suffering from essential thrombocythemia or from primary myelofibrosis. The V617F mutation is thought to provide
hematopoietic stem cells and myeloid progenitors with a survival and proliferation advantage. It has previously
been shown that activated JAK2 promotes cell survival by upregulating the anti-apoptotic STAT5 target gene Bcl-
xL. In this study, we have investigated the role of additional apoptotic players, the pro-apoptotic protein Bim as
well as the anti-apoptotic protein Mcl-1.
Methods: Pharmacological inhibition of JAK2/STAT5 signaling in JAK2
V617F mutant SET-2 and MB-02 cells was used
to study effects on signaling, cell proliferation and apoptosis by Western blot analysis, WST-1 proliferation assays
and flow cytometry. Cells were transfected with siRNA oligos to deplete candidate pro- and anti-apoptotic proteins.
Co-immunoprecipitation assays were performed to assess the impact of JAK2 inhibition on complexes of pro- and
anti-apoptotic proteins.
Results: Treatment of JAK2
V617F mutant cell lines with a JAK2 inhibitor was found to trigger Bim activation.
Furthermore, Bim depletion by RNAi suppressed JAK2 inhibitor-induced cell death. Bim activation following JAK2
inhibition led to enhanced sequestration of Mcl-1, besides Bcl-xL. Importantly, Mcl-1 depletion by RNAi was
sufficient to compromise JAK2
V617F mutant cell viability and sensitized the cells to JAK2 inhibition.
Conclusions: We conclude that Bim and Mcl-1 have key opposing roles in regulating JAK2
V617F cell survival and
propose that inactivation of aberrant JAK2 signaling leads to changes in Bim complexes that trigger cell death.
Thus, further preclinical evaluation of combinations of JAK2 inhibitors with Bcl-2 family antagonists that also tackle
Mcl-1, besides Bcl-xL, is warranted to assess the therapeutic potential for the treatment of chronic
myeloproliferative neoplasms.
Background
The somatic activating JAK2
V617F mutation is found in
nearly every patient with the chronic myeloproliferative
neoplasm (cMPN) polycythemia vera (PV) and roughly
half of those patients affected by essential thrombo-
cythemia (ET) and primary myelofibrosis (PMF) [1]. At
the molecular level, it is thought that the V617F muta-
tion in the JAK2 pseudokinase alleviates some of the
negative regulation that this domain normally elicits on
the kinase domain [2], allowing for increased kinase
autoactivation [3]. Clinical trials with JAK inhibitors in
primary myelofibrosis patients are underway and have
shown rapid suppression of splenomegaly and improve-
ment of constitutional symptoms [4]. However, up to
now effects on mutant allele burden have been modest
and bone marrow fibrosis appears to persist [5], war-
ranting continued pre-clinical and clinical research in
order to improve therapeutic outcome of JAK inhibitors
in cMPNs. Mutant JAK2
V617F, which arises at the level
of the hematopoietic stem cell [6], likely provides pro-
genitor cells with both a proliferation and a survival
advantage [7]. Hence, a potential avenue for enhanced
JAK2
V617F cell killing by JAK2 inhibitors may lie in
simultaneous perturbation of survival mechanisms.
Importantly, several studies have found that the anti-
apoptotic Bcl-2 family member Bcl-xL plays a role in
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depletion induced apoptosis in JAK2
V617F mutant cells
and the BH3 (Bcl-2-homology domain 3)-mimetic ABT-
737 was shown to preferentially kill JAK2
V617F mutant
PV erythroid precursors as compared to healthy subject
erythroblasts [9,10]. The BH3-only pro-apoptotic protein
Bad has been implicated in regulating JAK2
V617F mutant
cell survival [10] and engages anti-apoptotic Bcl-2, Bcl-
xL and Bcl-w, but not Mcl-1 [11]. Mcl-1 protein is nor-
mally short-lived due to rapid proteasome-mediated
destruction but contributes to resistance to cell-death
stimuli if its levels are elevated [12,13].
In this study we focused on elucidating potential roles
of pro-apoptotic Bim and anti-apoptotic Mcl-1 in regu-
lating JAK2
V617F mutant cell survival. In contrast to Bad,
Bim can engage all Bcl-2 pro-survival family members,
including Mcl-1 [11]. Both Bim and Mcl-1 were readily
detectable in JAK2
V617F mutant cell lines and co-immu-
noprecipitated. JAK2 inhibition led to changes in Bim-
EL Ser69 phosphorylation, along with a drop in total
Mcl-1 levels and concomitant induction of programmed
cell death. In support of a key role in regulating
JAK2
V617F cell survival, Mcl-1 depletion by RNAi was
found to severely compromise cell viability and sensi-
tized cells to JAK2 inhibition. Taken together, we show
that Mcl-1 appears to be critical for JAK2
V617F mutant
cell survival, and corroborate that cell death induced by
JAK2 inhibition requires Bim activation. Our findings
suggest that combinations of JAK2 inhibitors with Bcl-2
family antagonists that tackle both Bcl-xL and Mcl-1
merit further preclinical evaluation of the therapeutic
potential for the treatment of cMPNs.
Methods
Compounds and formulations
NVP-BSK805 (free base) was synthesized internally [14],
10 mM stock solutions were prepared in dimethyl sulf-
oxide (DMSO) and aliquots were stored at -20°C until
use. The ethyl-ester of the pan-caspase inhibitor
Z-VAD-FMK was synthesized internally. UO126 (# 1144,
Tocris Bioscience, Ellisville, MO, USA) was prepared as a
10 mM stock solution in DMSO and stored at -20°C
until use. Obatoclax mesylate (# S1057, Selleck Chemi-
cals, Houston, TX, USA) was prepared as a 10 mM stock
solution in DMSO and stored at -20°C until use.
Cell culture
SET-2 cells (generously provided by Prof. Hans Drexler,
DSMZ, Braunschweig, Germany) were cultured in stan-
dard RPMI medium supplemented with 10% of fetal calf
serum (FCS), 2 mM L-glutamine and 1% (v/v) penicil-
lin/streptomycin. MB-02 cells (generously provided by
Prof. Doris Morgan, Drexel University, Philadelphia, PA,
USA) were grown in RPMI medium as described above,
supplemented with 10 ng/ml recombinant human
GM-CSF (granulocyte-macrophage colony-stimulating
factor), 10 ng/ml recombinant human SCF (stem cell
factor) and 10 mM sodium pyruvate. TF-1 cells (Ameri-
can Type Culture Collection) were cultured in RPMI
medium, supplemented with 20% of fetal bovine serum,
1 mM L-glutamine, 5 g/l sodium bicarbonate, 10 mM
HEPES, 1 mM sodium pyruvate, 4.5 g/l D-glucose, 1%
(v/v) penicillin/streptomycin and 2 ng/ml GM-CSF.
RNA interference
The following stealth™ RNAi oligonucleotides (Invitro-
gen, Carlsbad, CA, USA) were used; BAD: duplex 1 5’-
GCUCCGGAGGAUGAGUGACGAGUUU-3’,d u p l e x2
5’-GGACUCCUUUAAGAAGGGACUUCCU-3’ and
duplex 3 5’-UCUUCCAGUCCUGGUGGGAUCGGAA-
3’;B i m :d u p l e x15 ’-UGAGUGUGACCGAGAAGG
UAGACAA-3’,d u p l e x25 ’-CAUGAGUUGUGACAA-
AUCAACACAA-3’ and duplex 3 5’-CACGAAUG-
GUUAUCUUACGACUGUU-3’;M c l - 1 :d u p l e x15 ’-
GAAAGUAUCACAGACGUUCUCGUAA-3’,d u p l e x2
5’-CGGGACUGGCUAGUUAAACAAAGAG-3’ and
duplex 3 5’-GGUUUGUGGAGUUCUUCCAUGUAGA-
3’, and a non-targeting control stealth™ RNAi oligo 5’-
GAUGAAGGGAGGGUGUACCAACUUA-3’. Cells were
transfected with RNAi oligonucleotides using Nucleofac-
tor™ Solution V (Amaxa GmbH, Cologne, Germany)
and the Amaxa system according to the instructions of
the manufacturer.
Real-Time Quantitative PCR
Mcl-1 mRNA levels were determined by real-time quan-
titative PCR using the Applied Biosystems Taqman
Gene Expression kit (# Hs03043899_m1, Applied Bio-
systems, Carlsbad, CA, USA). Total RNA from cells was
isolated with the RNeasy Mini Kit (# 74104, Qiagen,
Hilden, Germany), accompanied by an on-column
DNase (# 79254, Qiagen) digestion. Expression levels of
the housekeeping gene GAPDH (# 4310884E, Applied
Biosystems) were also measured as an endogenous nor-
malization control. Mcl-1 and GAPDH signals were
measured with FAM (6-carboxy-fluorescein) and VIC
fluorescent reporter dye labeling, respectively. The
volume of each reaction was 10 μl per well (384-well
plate), which consisted of 5 μl 2 × reaction buffer and
0.05 μl 200 × Euroscript RT (reverse transcriptase)
enzyme and RNase inhibitor mix from the one-step RT-
qPCR MasterMix Plus (# RT-QPRT-032X, Eurogentec,
Seraing, Belgium), 0.5 μl 20 × Taqman Gene Expression
mix together with 2 μl of 50 ng RNA as amplification
template. The ROX reference dye was present in the
RT-qPCR reaction buffer. RT-qPCR was carried out on
the ABI 7900HT Fast Real-Time PCR system (Applied
Biosystems, SDS2.3 software). The reaction mixtures
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the reverse transcription took place, 95°C for 10 minutes
to activate HotGoldStar DNA polymerase (Eurogentec),
followed by 40 cycles at 95°C for 15 seconds and 60°C
for 1 minute. Samples were measured in triplicate. Cycle
threshold (Ct) values were used to determine the rela-
tive amounts of Mcl-1 and GAPDH mRNA levels in the
samples. 2
-Ct Mcl-1 values were computed and normal-
ized to mean 2
-Ct GAPDH values. Mcl-1 mRNA levels
were depicted as fold change compared to DMSO vehi-
cle control by dividing normalized 2
-Ct values of com-
pound treated samples by those of vehicle treated
samples.
Western blotting
Cells were extracted in lysis buffer (50 mM HEPES pH
7.4, 150 mM NaCl, 25 mM b-glycerophosphate, 25 mM
N a F ,5m ME G T A ,1m ME D T A ,1 5m Mp y r o p h o -
sphate PPI, supplemented freshly with 1% Nonidet P-40,
1 x protease inhibitor cocktail (Complete Mini, Roche),
1 mM DTT, 0.2 mM sodium-vanadate and 1 mM
PMSF) by passing through a 1 ml syringe connected to
a 23-gauge needle. Cell debris were pelleted by centrifu-
gation. Typically, 20 μg of protein lysates were resolved
by NuPAGE Novex 4-12% Bis-Tris Midi Gels (Invitro-
gen, Carlsbad, CA, USA) and transferred to PVDF mem-
branes by semi-dry blotting. The following antibodies
were used to probe blots: Anti-cleaved caspase 3
(# 9664), 7 (# 9491), 8 (# 9496), 9 (# 9501), Bad (#9292),
Bak (# 3814), Bax (# 2772), Bcl-xL (# 2762), Bim
(# 2933), phospho-Bim (Ser55 (Homo sapiens: Ser59)
(# 4550), phospho-Bim (Ser69) (# 4581), ERK1/2 (# 9102),
phospho-ERK1/2 (Thr201/Tyr204) (9101), Mcl-1 (# 4572),
PARP (# 9542), phospho-STAT5 (# 9359) and phospho-
tyrosine (# 9411) were from Cell Signaling Technology
(Beverly, MA, USA). Anti-Bim (# 202000) from Calbio-
chem (San Diego, CA, USA) was also used. The STAT5
antibody (# sc-835) was from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The b-tubulin (# T4026) and
Mcl-1 (# AAP-240) antibodies were from Sigma (St.
Louis, MO, USA) and Assay Designs (Ann Arbor, MI,
USA), respectively. Antibodies were typically incubated
overnight at 4°C followed by washes and incubation with
the corresponding HRP-conjugated secondary antibodies.
Immunoreactive bands were revealed with enhanced che-
miluminescence reagents.
Immunoprecipitation and co-immunoprecipitation assays
Cells were extracted either in CHAPS lysis buffer [15] or
in Triton/glycerol ("TG”) lysis buffer [16] (the latter for
Bcl-xL/Bax co-immunoprecipitation studies), lysates
were kept on ice and protein content was determined by
Bradford assay. Immediately thereafter, typically 500 μg
total protein input were subject to immunoprecipitation
using the following antibodies: Anti-Bim (# 2933), anti-
Bcl-xL (# 2762) and anti-Bax (# 2772) were from Cell
Signaling Technology (Beverly, MA, USA), anti-Mcl-1
(# 559027) from BD Biosciences (Franklin Lakes, NJ,
USA). Co-immunoprecipitation assays were carried out
using 1.5 ml Eppendorf protein LoBind Tubes (# 0030
108.116, Eppendorf, Hamburg, Germany). Bound frac-
tions were released by heating at 70°C for 10 minutes in
20 μl NuPAGE LDS sample buffer. The supernatant con-
taining the bound fraction was resolved by gradient gel
electrophoresis and transferred to PVDF membranes for
Western blot analysis as described above.
Proliferation assays
Anti-proliferative activity of the JAK2 inhibitor NVP-
BSK805 was determined by incubating SET-2 cells or
MB-02 cells with an 8 point concentration range of
compound and cell proliferation relative to DMSO trea-
ted cells was measured (typically after 72 hours for
SET-2 cells and after 96 hours for MB-02 cells, unless
specified otherwise) using the colorimetric WST-1
(Roche Diagnostics GmbH, Penzberg, Germany) cell via-
bility readout. Of each triplicate treatment the mean
was calculated and these data were plotted in XLfit 4
(XLfit 4, ID Business Solutions Ltd, Guildford, Surrey,
UK) to determine the respective half-maximal growth-
inhibitory concentration (GI50) values.
Flow cytometry
Cultured cells were collected after treatments, washed
once with PBS and resuspended in propidium iodide
buffer (1 mM sodium citrate (pH 4.0), 1.5 mM NaCl,
5 mM EDTA, 5 mM EGTA, 0.1% NP40, 4 μgo fp r o p i -
dium iodide/ml and 80 μg/ml of RNaseA in PBS).
After 30 minutes of incubation in the dark on ice, cel-
lular DNA content was measured with a BD FACSCali-
bur flow cytometer (BD Biosciences, San Jose, CA,
USA). For detection of activated Bak, cells were
washed in PBS and then fixed at RT for 5 minutes in
0.25% paraformaldehyde (diluted in PBS). After wash-
ing twice with PBS the cell pellet was resuspended in
200 μl PBS containing 0.1% digitonin (# D141, Sigma)
and then 10 μl mouse anti-Bak antibody (# AM03 (Ab-1),
Calbiochem) were added followed by incubation on ice
for 30 minutes. After washing twice with PBS the cell
pellet was resuspended in 100 μl PBS and incubated at
room temperature in the dark for 40 minutes with 5 μl
fluorescein isothiocyanate (FITC)-conjugated anti-
m o u s ea n t i b o d y( #s c - 2 0 1 0 ,S a n t aC r u z )f o l l o w e db y
two washes with PBS and flow cytometry analysis. The
shifts in fluorescent channel 1-height (FL1-H) fluores-
cence intensity compared to DMSO vehicle controls
were quantified and represented as fold change over
DMSO control.
Rubert et al. BMC Cancer 2011, 11:24
http://www.biomedcentral.com/1471-2407/11/24
Page 3 of 14Statistical analysis
The t-test was conducted to determine statistical signifi-
cance between two groups. The significance level was
set at p < 0.05. Statistical analysis was performed using
SigmaPlot v11.0 (Systat Software Inc, Chicago, IL, USA).
Results
NVP-BSK805 JAK2 inhibitor triggered cell death requires
activation of caspase cascades and is overcome by
caspase inhibition
We have previously shown that the JAK2 inhibitor tool
compound NVP-BSK805 blunts constitutive STAT5 phos-
phorylation in JAK2
V617F mutant cell lines, reduces Bcl-xL
levels and blocks cell proliferation with concomitant induc-
tion of cell death [17]. To corroborate that NVP-BSK805
induces programmed cell death in JAK2
V617F mutant cell
lines, we assessed if apoptosis would be overcome by phar-
macological inhibition of caspases. To this end we used
SET-2 and MB-02 cells, which bear mutated JAK2
V617F
and have been derived from leukemia patients with a pre-
vious history of essential thrombocythemia and myelofi-
brosis, respectively [18,19]. SET-2 and MB-02 cells were
pretreated for 1 hour with increasing concentrations of a
pan-caspase inhibitor, followed by treatment with 0.5 μM
NVP-BSK805 for 24 hours. In both cell lines the caspase
inhibitor elicited a concentration-dependent suppression
of JAK2 inhibitor-triggered PARP cleavage (Figure 1A
and 1B). A concentration of 200 μM of the caspase inhibi-
tor was found to completely counteract PARP-cleavage as
a result of JAK2 inhibition in both cell lines. Both SET-2
and MB-02 cells respond sensitively to JAK2 inhibition by
NVP-BSK805 in cell proliferation assays over 72 and 96
hours, respectively [17], and this anti-proliferative response
is blunted by caspase inhibition (Figure 1C and 1D).
Apoptosis is executed by caspase cascades of the so-
called intrinsic and extrinsic pathways that activate cas-
pase 9 and 8, respectively [20]. In order to assess (i) the
timing of caspase induction following JAK2 inhibition
and (ii) dissect the caspase cascades triggering cell
death, SET-2 and MB-02 cells lines were treated with
NVP-BSK805 and extracted at different points in time.
In both cell lines PARP cleavage became evident at the
16 hours time point, coinciding with the detection of
cleaved caspases 9 and 8, as well as cleaved effector cas-
pases 3 and 7 (Figure 2). These results imply that pro-
grammed cell death triggered by JAK2 inhibition in the
JAK2
V617F mutant cell lines involves both the intrinsic
and extrinsic pathways.
Key role of Bim in JAK2 inhibitor induced apoptosis in
JAK2
V617F cells
To gain more insights into the apoptotic players
involved in triggering the caspases of the intrinsic path-
way in JAK2
V617F cell lines, we tested the impact of Bad
depletion on JAK2 inhibitor-induced apoptosis. Bad and
Bcl-xL have previously been shown to play a role in
SET-2 cell survival [10]. In agreement with these earlier
reports, Bad depletion by RNAi partially suppressed
apoptosis induction in SET-2 cells, as assessed by PARP
cleavage and measuring the sub-G1 cell fraction by flow
cytometry, following JAK2 inhibition (Figure 3A and
3C). However, in MB-02 cells Bad depletion only
modestly suppressed NVP-BSK805-induced cell death
(Figure 4A and 4C). Intrigued by this finding, we
explored the role of Bim, another BH3-only protein, in
JAK2 inhibitor-induced apoptosis. In both cell lines,
Bim levels were readily detected at baseline and strongly
reduced following RNAi (Figure 2, 3A and 4A). In both
SET-2 and MB02 cells Bim-EL was the predominant
isoform expressed (Figure 3B and 4B). Importantly,
Bim-depleted SET-2 and MB-02 cells were largely resis-
tant to cell death by NVP-BSK805 (Figure 3C and 4C).
Similarly, Will et al. recently reported that shRNA-
mediated Bim depletion suppressed apoptosis induced
by JAK2 inhibition in HEL cells [21]. In SET-2 cell pro-
liferation assays, Bim depletion resulted in a three-fold
increase in the GI50 (half-maximal growth-inhibitory
concentration) of NVP-BSK805 (Figure 3D). In agree-
ment with a recent report [21], these findings corrobo-
rate a crucial role for Bim in the execution of cell death
in JAK2
V617F mutant cells.
JAK2 inhibition in JAK2
V617F cells modulates the post-
translational modification of Bim and levels of Mcl-1
Upon incubation of JAK2
V617F mutant cell lines with
NVP-BSK805, we noticed that Mcl-1 levels started to
drop at the 16 hours time point, paralleling the activa-
tion of caspases and PARP cleavage (Figure 2). Mcl-1 is
ap r o t e i nw i t har e l a t i v e l ys h o r th a l f - l i f ea n dh a sb e e n
shown to be dynamically regul a t e da tt h el e v e lo ft r a n -
scription by STAT3/STAT5 signaling [22] and at the
post-translational level by phosphorylation and polyubi-
quitination [23,24] to signal destruction by the protea-
some. To test the dynamics of Mcl-1 levels in JAK2
V617F
cells as compared to factor-dependent cells with wild-
type JAK2, we transiently blocked signaling from JAK2
to STAT5 in both contexts. Consistent with previous
reports [22,25] Mcl-1 levels dropped upon starvation
of TF-1 erythroleukemia cells with wild type JAK2
and recovered upon re-stimulation with GM-CSF, corre-
lating with the changes in STAT5 phosphorylation
(Figure 5A). This was very similar to the drop seen in
Mcl-1 levels in JAK2
V617F-bearing SET-2 cells after 16
hours of treatment with NVP-BSK805 and re-induction
of Mcl-1 after compound washout and release of the
cells into fresh medium for 8 hours (Figure 5A). Treat-
ment of SET-2 cells with NVP-BSK805 also led to
ar e d u c t i o no fMcl-1 transcript levels, as assessed by
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control of Mcl-1 levels in cells with wild type JAK2 [22]
appears to be maintained in JAK2
V617F mutant cells.
As alluded to above, Bim-EL levels were readily
detectable in SET-2 and MB-02 cell lines at baseline
and did not increase appreciably upon JAK2 inhibitor
treatment (Figure 2A and B). This was reminiscent of
the modest changes in Bim-EL levels reported in IL-3
dependent mouse pro-B FL5.12 cells following IL-3
deprivation [26]. Thus, we investigated if the association
of Bim with Mcl-1 and/or Bcl-xL [15,16] would be
impacted by JAK2 inhibition. Using SET-2 JAK2
V617F
mutant cell extracts, we found that Mcl-1 co-immuno-
precipitated with Bim and vice versa (Figure 5B). Impor-
tantly, despite a drop in total and immunoprecipitatable
Mcl-1 levels in JAK2
V617F mutant cells treated with
NVP-BSK805, the relative ratio of Bim immunoprecipi-
tated with Mcl-1 appeared constant or even increased
compared to control cell extracts, indicating enhanced
association of Bim and Mcl-1 upon JAK2 inhibition
(Figure 5B). Interestingly, the amounts of Mcl-1 that
could be immunoprecipitated from cells treated with
NVP-BSK805 were already strongly reduced at the
4 hours time point (Figure 5B), at which total levels in
whole cell extracts were not yet substantially lower com-
pared to control cells (Figure 5C). The importance of
Bcl-xL in regulating survival of JAK2
V617F cells has
already been recognized [10,27,28], hence, we also
assessed its interaction with Bim [16]. Similar to the
results obtained with Mcl-1, the relative amounts of Bcl-
xL co-immunoprecipitated with Bim were comparable
between extracts prepared from control and JAK2
Figure 1 Caspase inhibition rescues JAK2
V617F mutant cells from the apoptotic and anti-proliferative effects of the JAK2 inhibitor NVP-
BSK805. SET-2 (A) and MB-02 (B) cells were pretreated for 1 hour with increasing concentrations of a pan-caspase inhibitor, followed by
treatment for 24 hours with 500 nM NVP-BSK805. PARP cleavage (cleaved PARP is depicted by arrowheads) was assessed by Western blot
analysis. b-tubulin was probed for as a loading control. Controls consisted of drug vehicle (DMSO) treated cells (baseline) and NVP-BSK805
treatment in the absence of the pan-caspase inhibitor. Proliferation assays with increasing concentrations of NVP-BSK805 in SET-2 (C) and MB-02
(D) cells were carried out in the absence (empty triangles/solid line) or presence (filled circles/stippled line) of 200 μM pan-caspase inhibitor.
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all levels of Bcl-xL after 24 hours of drug treatment
(Figure 5C). Using an antibody that recognizes an
amino-terminal epitope of human Bax, there was a pro-
nounced increase in the amounts of detergent-soluble
Bax that could be immunoprecipitated after treatment
of SET-2 cells with NVP-BSK805 (Figure 5D), while the
total levels of Bax were unchanged (Figure 5C). Levels
of detergent-soluble Bax that could be immunoprecipi-
tated reached a plateau by 48 hours following JAK2
inhibition (Additional file 2). These findings imply either
a change of Bax conformation, or a change of multi-
protein complexes containing Bax, or both upon JAK2
inhibition. In support of changes in Bim/Bcl-xL/Bax
complexes following JAK2 inhibition, lower amounts of
Bax co-immunoprecipitated with Bcl-xL from cells trea-
ted with NVP-BSK805 (Figure 5D). Mcl-1 was not
found to co-immunoprecipitate Bax (data not shown).
Importantly, besides Bax also Bak needs to be activated
to trigger mitochondrial cell death [11] and Mcl-1 has
been described to antagonize Bak at the mitochondrial
membrane [29]. Since both Bax and Bak are expressed
in SET-2 cells (Figure 5C) we investigated Bak activation
following JAK2 inhibition. To this end, we carried out
co-immunoprecipitation experiments to study the inter-
action of Bak with either Mcl-1 or Bcl-xL. Unfortu-
nately, these analyses were confounded by unspecific
binding of Bak to the beads. Thus, we assessed Bak acti-
vation by flow cytometry using a conformation-specific
Bak antibody [29]. These analyses revealed significant
Bak activation in SET-2 cells starting at 24 hours follow-
ing JAK2 inhibition (Figure 5E).
We noticed faster migration of Bim-EL in SDS-PAGE
upon JAK2 inhibitor treatment (Figures 2, 3, 4, 5 and 6),
indicative of changes in post-translational modification
(s) [26]. Bim-EL contains a number of Ser/Thr-Pro con-
sensus motif phosphorylation sites and phosphorylation
on serine 69 by the MEK/ERK pathway was shown to
regulate Bim activity/stability [26,30]. We assessed Bim
Ser69 phosphorylation in SET-2 cells and found that
this site was strongly modulated following JAK2 inhibi-
tion (Figure 6A), likely accounting for the changes seen
in Bim-EL electrophoretic mobility, and in agreement
with a recent report [21]. Phosphorylation on additional
Ser/Thr-Pro sites has been reported to contribute to
Bim-EL band-shifting in mouse pro-B FL5.12 cells [26].
Figure 2 Activation of intrinsic and extrinsic caspase cascades following JAK2 inhibition in JAK2
V617F mutant cells lines.S E T - 2( A)a n d
MB-02 (B) cells were treated with 500 nM of the JAK2 inhibitor NVP-BSK805 and extracted at the indicated time points for Western blot analysis.
Control (Ctrl) cells were treated with the drug vehicle DMSO for 72 hours. Induction of apoptosis markers becomes evident starting at the 16
hours time point in both cell lines. Arrowhead denotes cleaved PARP, running below the band for full-length PARP. The caspase-8 blot shows
the p43/p41 cleavage intermediates and active caspase-8 fragment p18.
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V617F mutant SET-2 cells suppress NVP-BSK805-induced apoptosis. A:S E T - 2c e l l sw e r e
transfected with control siRNA (Ctrl), Bad siRNA or siRNAs to deplete both Bad and Bim simultaneously. After 72 hours, cells were treated with
500 nM NVP-BSK805 or the drug vehicle DMSO for 30 hours and extracted for Western blot analysis. Arrowhead depicts cleaved PARP running
below the full-length PARP protein. b-tubulin was probed for as a loading control. B: SET-2 cells were transfected with control siRNA (Ctrl) or Bim
siRNA and analyzed as described above. The Bim Western blot depicts an extended molecular weight range to show that Bim-EL is the
predominant form of the protein expressed in SET-2 cells. C: SET-2 cells were transfected with control, Bad or Bim siRNAs, or siRNAs to deplete
both Bad and Bim simultaneously, for 48 hours and then treated with 1 μM NVP-BSK805 or the drug vehicle DMSO for 40 hours. Controls also
consisted of non-transfected cells. Then, DNA content was measured by FACS using propidium iodide (PI) staining and the percentage of cells
with less than 2N DNA content was determined (data represent the mean ± SD of three independent experiments). *Significantly different from
respective DMSO control using t-test (p < 0.05).
#Significant difference between groups as assessed by t-test (p < 0.05). D: SET-2 cells were
transfected with control, Bad or Bim siRNAs, or siRNAs to deplete both Bad and Bim simultaneously, for 24 hours and then treated with
increasing concentrations of NVP-BSK805 in cell proliferation assays for 48 hours. The histogram depicts half-maximal growth-inhibitory (GI50)
concentrations of NVP-BSK805 for each condition (data represent the mean ± SD of two independent experiments carried out in triplicate).
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V617F mutant MB-02 cells suppresses NVP-BSK805-induced apoptosis. A: MB-02 cells were transfected with
control siRNA (Ctrl), Bad siRNA or siRNAs to deplete both Bad and Bim simultaneously. After 72 hours, cells were treated with 500 nM NVP-
BSK805 or the drug vehicle DMSO for 16 hours and extracted for Western blot analysis. Arrowhead depicts cleaved PARP running below the full-
length PARP protein. b-tubulin was probed for as a loading control. B: MB-02 cells were transfected with control siRNA (Ctrl) or Bim siRNA and
analyzed as described above. The Bim Western blot depicts an extended molecular weight range to show that Bim-EL is the predominant form
of the protein expressed in MB-02 cells. C: MB-02 cells were transfected with control, Bad or Bim siRNAs, or siRNAs to deplete both Bad and Bim
simultaneously, for 48 hours and then treated with 1 μM NVP-BSK805 or the drug vehicle DMSO for 40 hours. Controls also consisted of non-
transfected cells. Then, DNA content was measured by FACS using propidium iodide (PI) staining and the percentage of cells with less than 2N
DNA content was determined (data represent the mean ± SD of three independent experiments). *Significantly different from respective DMSO
control using t-test (p < 0.05).
#Significant difference between groups as assessed by t-test (p < 0.05).
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Page 8 of 14Figure 5 Analysis of the regulation of anti-apoptotic and pro-apoptotic proteins in JAK2
V617F mutant SET-2 cells. A: JAK2 wild type TF-1
cells (left panels) were starved overnight in medium containing 0.1% FCS without GM-CSF. Cells were then stimulated with 2 ng/ml GM-CSF
(+GM) for 8 hours and extracted. Control TF-1 cell extracts (Ctrl) were prepared from cells growing in full medium. SET-2 cells (right panels) were
treated with DMSO (Ctrl) or 500 nM NVP-BSK805 for 16 hours. Cells were either extracted or washed and released into fresh medium (FM)
without NVP-BSK805 for 8 hours and then extracted. B: SET-2 cells were treated with DMSO or 500 nM NVP-BSK805 for 4 or 24 hours, extracted,
and lysates were subjected to co-immunoprecipitation studies. To control for potential unspecific binding of the proteins of interest to beads,
extracts (same total protein input as used for the immunoprecipitations) were also incubated with beads without the respective antibodies (Ctrl).
C: Levels of soluble Bak, Bax, Mcl-1, Bcl-xL and Bim in SET-2 whole cell extracts following treatment of cells for 4 and 24 hours with DMSO or
NVP-BSK805. D: SET-2 cell lysates from cells treated as described above in panel B were subjected to immunoprecipitation of Bax (using an
antibody recognizing an amino-terminal epitope) and co-immunoprecipitation studies. Potential unspecific binding of the proteins of interest to
beads was controlled (Ctrl) as described above. E: SET-2 cells were incubated with DMSO for 48 hours or with 500 nM NVP-BSK805 for the
indicated times. Bak activation was assessed using a Bak active conformation-specific antibody by flow cytometry analysis. Results are depicted as
the means of three independent experiments ± SD. *Significantly different from DMSO control using t-test (p < 0.05). **Significantly different
from DMSO control using t-test (p < 0.001).
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Page 9 of 14However, we did not detect Bim Ser59 phosphorylation
(Figure 6A) or Bim tyrosine phosphorylation (data not
shown and [31]). In support of the MEK/ERK pathway
mediating Bim phosphorylation, downstream of aberrant
JAK2 signaling, treatment of SET-2 cells with the MEK
inhibitor UO126 impacted Bim-EL electrophoretic
mobility and Ser69 phosphorylation, comparable to that
seen upon NVP-BSK805 treatment (Figure 6B).
Mcl-1 is required for survival of JAK2
V617F cells
To further test the extent to which Mcl-1 plays a role in
JAK2
V617F mutant cell survival we used approaches
involving pharmacological inhibition and RNAi. Incuba-
tion of SET-2 cells with sub-optimal concentrations of
the pan-Bcl-2 family protein inhibitor obatoclax [32] in
cell proliferation assays lowered the GI50 of NVP-
BSK805 by 3 to 4 fold (Figure 7A). Since obatoclax also
inhibits other Bcl-2 members, besides Mcl-1, and might
exhibit off-target effects [33], we expanded on these
results by specifically depleting Mcl-1 using RNAi.
Importantly, Mcl-1 depletion increased apoptosis in
JAK2
V617F mutant SET-2 cells and sensitized the cells to
NVP-BSK805-induced cell death as assessed by Western
blot analysis and measuring the sub-G1 cell fraction by
flow cytometry (Figure 7B and 7C). The latter finding
was corroborated in cell proliferation assays. 24 hours
after transfection of SET-2 cells with either non-target-
ing RNAi oligos or oligos directed towards the Mcl-1
transcript, cells were treated with increasing concentra-
tions of NVP-BSK805 for 48 hours. Notably, Mcl-1
depleted SET-2 cells had an approximately 4-fold lower
GI50 value as compared to SET-2 cells transfected with
control oligos (Figure 7D). Similarly, obatoclax or Mcl-1
depletion by RNAi also strongly affected viability of
MB-02 cells and sensitized them to JAK2 inhibition by
NVP-BSK805 (data not shown).
Discussion
In malignant and normal cells the balance between pro-
apoptotic and anti-apoptotic signals determines cell sur-
vival. The JAK2
V617F mutation was identified with high
frequencies in the MPNs PV, ET as well as PMF, and is
thought to provide mutant progenitor cells with a prolif-
eration and survival advantage [7]. In the present study,
we have focused on assessing the roles of the pro-apop-
totic protein Bim and the anti-apoptotic protein Mcl-1
in JAK2
V617F mutant cells. We report that Bim depletion
by RNAi suppresses JAK2 inhibitor-induced apoptosis,
while Mcl-1 depletion profoundly affects JAK2
V617F
mutant cell viability and sensitizes cells to JAK2 inhibi-
tion. The BH3-only protein Bim plays an important role
in hematopoietic homeostasis [34] and has been shown
to be regulated by factors that activate JAK2 signaling
[26,35]. Two cooperating pathways downstream of JAK2
activation have been reported to keep Bim activity in
check; On one hand, PI3K/AKT signaling regulates the
expression of the Bim gene via the forkhead transcrip-
tion factor FOXO3A [36,37], whereas on the other
hand, MEK/ERK signaling promotes Bim phosphoryla-
tion on Ser69 and triggers its degradation by the protea-
some [30]. Furthermore, it was recently found that Bim
expression in erythroblasts is suppressed by the LRF
transcription factor (itself being a direct target of
GATA1) in the process of erythroid maturation [38].
Mcl-1 is a member of five anti-apoptotic proteins (Bcl-2,
Bcl-xL, Bcl-W, Mcl-1 and A1) that antagonize the pro-
apoptotic proteins Bak and Bax [39]. Mcl-1 has a chief
role in regulating the survival of hematopoietic stem
cells and early hematopoietic progenitors [40]. Bcl-xL
has an important role in protecting hematopoietic cells
and maturing erythroid cells from cell death [41,42] and
is a target gene of EpoR/JAK2 signaling [43]. Mcl-1 and
Bcl-xL sequester Bak and Bax until their displacement is
promoted by the action of activated BH3-only proteins
to trigger subsequent mitochondrial cell death [29].
Here we show that JAK2 inhibition in JAK2
V617F
mutant cells led to post-translational changes in Bim
that affected its interaction with other Bcl-2 family
members. We detected enhanced association of Bim-EL
with Mcl-1 upon JAK2 inhibition, seemingly consistent
with earlier findings of apoptosis induction by serum
withdrawal [16]. Furthermore, there was a sharp
increase in the levels of immunoprecipitable Bax follow-
ing JAK2 inhibition. In various settings, Bim-EL activa-
tion also involves loss of MEK/ERK pathway-mediated
Figure 6 Analysis of Bim phosphorylation in JAK2
V617F mutant
SET-2 cells. A: SET-2 cells were treated with DMSO or 500 nM NVP-
BSK805 for 24 hours. Bim was immunoprecipitated and levels of
Bim-EL Ser69 as well as Ser59 phosphorylation were analyzed by
Western blotting. Levels of P-STAT5 and total STAT5 were probed
for as controls for the drug treatment. B: SET-2 cells were treated
with DMSO, 500 nM NVP-BSK805 or 10 μM UO126 for 4 hours.
Levels of P-STAT5, STAT5, P-ERK1/2 and ERK1/2 were assessed by
Western blotting. Bim was immunoprecipitated and levels of Bim-EL
Ser69 phosphorylation were detected by Western blotting.
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Page 10 of 14Ser69 phosphorylation, whereby Bim evades proteasomal
degradation [16]. Loss of Bim-EL Ser69 phosphorylation
following JAK2 inhibition in the JAK2
V617F mutant cell
lines analyzed in this study likely plays a role in Bim
activation, in agreement with a recent study by Will
et al. [21]. However, Will et al. reported that Bim
protein levels were up-regulated in JAK2
V617F mutant
cells following JAK2 inhibition [21], which we did not
see in our analyses. These differences might be attribu-
table to different experimental settings. In fact, using
factor-independent Ba/F3 pro-B cells stably expressing
EpoR and JAK2
V617F we also detected low basal levels of
Figure 7 Mcl-1 depletion in JAK2
V617F mutant SET-2 cells increases apoptosis and sensitizes the cells to NVP-BSK805-induced cell
death. A: Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid
line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/
stippled line) for 72 hours. B: SET-2 cells were transfected with control (Ctrl) or Mcl-1 siRNAs. After 48 hours cells were treated with DMSO or 500
nM NVP-BSK805 for 24 hours. Then, DNA content was measured by FACS using propidium iodide (PI) staining. The x- and y-axes represent
fluorescent channel 2-area (FL2-A) fluorescence intensity for PI staining and cell count, respectively. The percentage of cells in the respective cell
cycle phases is indicated for each treatment condition. C: SET-2 cells were transfected with control (Ctrl) or Mcl-1 siRNAs. After 48 hours, cells
were treated with 500 nM NVP-BSK805 or the drug vehicle DMSO for 24 hours and extracted for Western blot analysis. Arrowhead depicts
cleaved PAPR running below the full-length PARP protein. b-tubulin was probed for as a loading control. D: SET-2 cells were transfected with
control (Ctrl) or Mcl-1 siRNAs. After 24 hours cells were incubated for 48 hours with increasing concentrations of NVP-BSK805 to assess cell
proliferation relative to the respective DMSO treated controls.
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Page 11 of 14Bim-EL and a marked up-regulation upon JAK2 inhibi-
tion (data not shown), as found by Will et al. However,
Ba/F3 cells do not represent the hematopoietic lineage
in which the JAK2
V617F mutation arises and regulation
of Bim activity may be cell lineage-specific [26]. Taken
together, our findings imply that Bim is in a latent com-
plex with the Bcl-2 family pro-survival proteins Mcl-1
and Bcl-xL in viable JAK2
V617F mutant cells. Both Mcl-1
and Bcl-xL govern survival of JAK2
V617F mutant cells by
keeping Bax and Bak in check. In turn, JAK2 inhibition
is postulated to affect Bim complexes such that Mcl-1
and Bcl-xL are neutralized. This is proposed to drop
anti-apoptotic activity in JAK2
V617F mutant cells below a
critical threshold, unleashing Bak and Bax to drive mito-
chondrial cell death. Upon inhibition of JAK2/STAT sig-
naling the expression of Bcl-xL [44] and Mcl-1 [25,45] is
suppressed, along with subsequent reduction of Bcl-xL
and Mcl-1 protein levels, thereby contributing to the
loss of pro-survival activity. Hence, as in CML [46-48]
and FLT-3 mutant [49] AML cells, Bim is also emerging
as a central cell death driver in JAK2
V617F mutant cells
([21], and this report).
Polycythemia vera patients with high JAK2
V617F
mutant allele burden were described to have increased
levels of Bcl-2 as well as Bcl-xL, and the Bcl-2/Bcl-W/
Bcl-xL inhibitor ABT-737 was shown to preferentially
inhibit proliferation and induce mitochondrial depolari-
zation in JAK2
V617F mutant erythroblasts as compared
to those from healthy subjects [9]. However, at the level
of the individual MPN patient, Zeuner et al. did not
detect a strict correlation between Bcl-2 or Bcl-xL
expression and drug resistance, indicating that response
to therapy may be determined by additional underlying
anti-apoptosis mechanisms. Our findings suggest that
combinations of JAK2 inhibitors with Bcl-2 family
antagonists that also tackle Mcl-1, besides Bcl-xL
[21,50], merit further preclinical evaluation of the thera-
peutic potential for the treatment of cMPNs. Impor-
tantly, partial inhibition of Mcl-1 may be sufficient to
sensitize cells to JAK2 inhibition. This could be impor-
tant in order to minimize the impact on normal cells,
such as e.g. on B and T lymphocytes, in which Mcl-1
plays a key role, as revealed by conditional knock-out
studies [51]. Furthermore, it will be of particular interest
to explore if combinations of JAK2 inhibitors with Bcl-2
family antagonists result in enhanced killing of the MPN
mutant clone. Thus, follow-up experiments in suitable
preclinical MPN animal models [52-54] would be
important for proof of concept in vivo and to support
the translation of potentially promising therapeutic
modalities into the clinical setting. Encouragingly, clini-
cal assessment of JAK inhibitors in MPN patients is
underway [55], as well as intense drug discovery and
development efforts to identify Mcl-1 antagonists
[32,56].
Conclusions
Bim and Mcl-1 were found to have opposing roles in
regulating JAK2
V617F cell survival. JAK2 inhibition in
JAK2
V617F mutant cells led to loss of Bim-EL Ser69
phosphorylation, with concomitant enhanced sequestra-
tion of the Bcl-2 family proteins Mcl-1 and Bcl-xL. Con-
sistent with a key role of Bim in regulating apoptosis in
JAK2
V617F mutant cells, depletion of the BH3-only pro-
tein by RNAi markedly suppressed JAK2 inhibitor-
induced cell death. Vice versa, RNAi-mediated Mcl-1
depletion sensitized JAK2
V617F mutant cells to JAK2
inhibition. Thus, further preclinical assessment of com-
binations of JAK2 inhibitors with Bcl-2 family antago-
nists in models of cMPNs is warranted and antagonizing
Mcl-1, besides Bcl-xL, should be an integral part of such
strategies.
Additional material
Additional file 1: Supplementary Figure S1 - Reduction of Mcl-1
transcript levels following JAK2 inhibition by NVP-BSK805 in
JAK2
V617F mutant SET-2 cells. SET-2 cells were treated for 4 and 8
hours with 500 nM NVP-BSK805. Control cells were treated with the drug
vehicle DMSO for 4 hours. Total RNA was isolated and Mcl-1 transcript
levels were determined in triplicate by real-time quantitative PCR. Mcl-1
mRNA levels were normalized to GAPDH mRNA levels in the respective
samples and means ± SD were expressed as fold change compared to
the DMSO treated sample. Similar results were obtained in two
independent experiments.
Additional file 2: Time course of Bax activation following JAK2
inhibition by NVP-BSK805 in JAK2
V617F mutant cell lines. SET-2 (A)
and MB-02 (B) cells were treated with 500 nM of the JAK2 inhibitor NVP-
BSK805 and extracted at the indicated time points for
immunoprecipitation and Western blot analysis. Control (Ctrl) cells were
treated with the drug vehicle DMSO for 48 hours. Cells were extracted in
lysis buffer containing 1% CHAPS and Bax was immunoprecipitated using
an antibody that recognizes the amino-terminal epitope that is exposed
in the active conformation of Bax. Levels of immunoprecipitatable Bax at
the different time points following JAK2 inhibition were detected by
Western blotting. Western blot analysis was also used to assess levels of
Bax, PARP (cleaved PARP is depicted by arrowheads) and b-tubulin in
whole cell extracts. Results are representative of two independent
experiments.
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